PMID- 30922893
OWN - NLM
STAT- MEDLINE
DCOM- 20191210
LR  - 20210817
IS  - 1873-7064 (Electronic)
IS  - 0028-3908 (Print)
IS  - 0028-3908 (Linking)
VI  - 151
DP  - 2019 Jun
TI  - Sensitization to the prosocial effects of 3,4-methylenedioxymethamphetamine 
      (MDMA).
PG  - 13-20
LID - S0028-3908(18)30622-1 [pii]
LID - 10.1016/j.neuropharm.2019.03.017 [doi]
AB  - The recreational drug 3,4-methylenedioxymethamphetamine (MDMA) has well 
      documented prosocial effects and is currently under clinical investigation as a 
      treatment for patients with PTSD, autism, and other conditions. Early clinical 
      trials have found that MDMA-assisted therapy may have robust long-lasting 
      therapeutic effects, yet the mechanism by which acute treatments produce these 
      long-term effects is unclear. Sensitization to certain behavioral drug effects is 
      a common rodent model used to assess long-lasting neurobiological adaptations 
      induced by acute drug treatments. Nine independent experiments were undertaken to 
      investigate if and how mice sensitize to the prosocial effects of MDMA. When 
      treated with 7.8 mg/kg MDMA and paired every other day for a week, MDMA-induced 
      social interaction increased precipitously across treatment sessions. This 
      previously unreported phenomenon was investigated and found to be heavily 
      influenced by a social context and 5-HT(2A)R activation. Social sensitization did 
      not appear to develop if mice were administered MDMA in isolation, and 
      pretreatment with MDL100907, a selective 5-HT(2A)R antagonist, inhibited the 
      development of social sensitization. However, when MDL100907 was administered to 
      mice that had already been sensitized, it did not attenuate social interaction, 
      suggesting that 5-HT(2A)R activity may be necessary for the development of social 
      sensitization but not the expression of MDMA-induced social behavior. Additional 
      investigation is warranted to further explore the phenomenon of social 
      sensitization and to determine the underlying neurobiological mechanisms.
CI  - Copyright (c) 2019 Elsevier Ltd. All rights reserved.
FAU - Curry, Daniel W
AU  - Curry DW
AD  - Division of Neuropharmacology and Neurologic Diseases, Yerkes National Primate 
      Research Center, Emory University, Atlanta, GA, USA.
FAU - Berro, Lais F
AU  - Berro LF
AD  - Division of Neuropharmacology and Neurologic Diseases, Yerkes National Primate 
      Research Center, Emory University, Atlanta, GA, USA.
FAU - Belkoff, Andie R
AU  - Belkoff AR
AD  - Division of Neuropharmacology and Neurologic Diseases, Yerkes National Primate 
      Research Center, Emory University, Atlanta, GA, USA.
FAU - Sulima, Agnieszka
AU  - Sulima A
AD  - Drug Design and Synthesis Section, Molecular Targets and Medications Discovery 
      Branch, National Institute on Drug Abuse and the National Institute on Alcohol 
      Abuse and Alcoholism, Bethesda, MD, USA.
FAU - Rice, Kenner C
AU  - Rice KC
AD  - Drug Design and Synthesis Section, Molecular Targets and Medications Discovery 
      Branch, National Institute on Drug Abuse and the National Institute on Alcohol 
      Abuse and Alcoholism, Bethesda, MD, USA.
FAU - Howell, Leonard L
AU  - Howell LL
AD  - Division of Neuropharmacology and Neurologic Diseases, Yerkes National Primate 
      Research Center, Emory University, Atlanta, GA, USA; Department of Psychiatry and 
      Behavioral Science, Emory University School of Medicine, Atlanta, GA, USA. 
      Electronic address: lhowell@emory.edu.
LA  - eng
GR  - K05 DA031246/DA/NIDA NIH HHS/United States
GR  - P51 OD011132/OD/NIH HHS/United States
GR  - T32 DA015040/DA/NIDA NIH HHS/United States
GR  - Z01 DA000532/ImNIH/Intramural NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20190325
PL  - England
TA  - Neuropharmacology
JT  - Neuropharmacology
JID - 0236217
RN  - 0 (Fluorobenzenes)
RN  - 0 (Piperidines)
RN  - 0 (Serotonin Agents)
RN  - 0 (Serotonin Antagonists)
RN  - EW71EE171J (volinanserin)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Animals
MH  - Behavior, Animal/*drug effects
MH  - Fluorobenzenes/pharmacology
MH  - Male
MH  - Mice
MH  - Motor Activity/drug effects
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*pharmacology
MH  - Piperidines/pharmacology
MH  - Serotonin Agents/*pharmacology
MH  - Serotonin Antagonists/pharmacology
MH  - *Social Behavior
PMC - PMC8364737
MID - NIHMS1728422
OTO - NOTNLM
OT  - 3,4-methylenedioxymethamphetamine
OT  - 5-HT(2A)
OT  - MDMA
OT  - Sensitization
OT  - Social interaction
EDAT- 2019/03/30 06:00
MHDA- 2019/12/18 06:00
PMCR- 2021/08/15
CRDT- 2019/03/30 06:00
PHST- 2018/09/21 00:00 [received]
PHST- 2019/01/13 00:00 [revised]
PHST- 2019/03/13 00:00 [accepted]
PHST- 2019/03/30 06:00 [pubmed]
PHST- 2019/12/18 06:00 [medline]
PHST- 2019/03/30 06:00 [entrez]
PHST- 2021/08/15 00:00 [pmc-release]
AID - S0028-3908(18)30622-1 [pii]
AID - 10.1016/j.neuropharm.2019.03.017 [doi]
PST - ppublish
SO  - Neuropharmacology. 2019 Jun;151:13-20. doi: 10.1016/j.neuropharm.2019.03.017. 
      Epub 2019 Mar 25.